Ⓐ
PeptiBrief
Evidence Library
regulatory_label · 2025

EGRIFTA WR (tesamorelin) prescribing information

U.S. Food and Drug Administration · FDA Prescribing Information
regulatoryVerified
View source
Plain-English summary

Defines the licensed indication, product-specific administration requirements, contraindications, warnings and adverse effects.

Population
Adults with HIV-associated lipodystrophy
Intervention
Tesamorelin
Outcomes measured
Licensed indication|contraindications|warnings|adverse effects
Key findings
Tesamorelin is indication-specific and is not a general weight-loss medicine.
Limitations
Applies to the approved formulation and licensed indication rather than general weight loss or performance use.
Risk of bias
Low for regulatory status and approved safety information.
Citation
U.S. Food and Drug Administration (2025). EGRIFTA WR (tesamorelin) prescribing information. FDA Prescribing Information
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.